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Adolescents (aged 15 - 24 years) remain at the centre of the HIV/
AIDS epidemic in terms of infection rates, vulnerability and impact, 
with the Joint United Nations Programme on HIV/AIDS (UNAIDS) 
reporting 4 million adolescents living with HIV globally in 2016. [1] 
In eastern and southern Africa, young women and adolescent girls 
are disproportionately affected. Despite their recognition as a high-
priority group for HIV prevention, there was only a 6% drop in 
new infections among adolescent females between 2010 and 2015.[1] 
South Africa (SA) has one of the highest HIV prevalence rates in the 
world, with an estimated 18.9% of the population aged 15 - 49 years 
infected.[2] HIV incidence rates for women peak in the 15 - 24-year 
age group, while men reach peak rates 5 - 7 years later.[3,4] Individuals 
who acquire HIV infection at a young age have a greater probability 
of transmitting the virus than those who are infected when older, 
making the deployment of efficacious prevention strategies to 
adolescent females an urgent and compelling priority.[5,6]
Vaccination is the preferred prevention method for viral infections, 
and HIV vaccination prior to sexual debut has been identified as a 
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Background. HIV/AIDS remains a leading cause of death in adolescents (aged 15 - 25 years), and in sub-Saharan Africa HIV-related deaths 
continue to rise in this age group despite a decline in both adult and paediatric populations. This is attributable in part to high adolescent 
infection rates and supports the urgent need for more efficacious prevention strategies. In particular, an even partially effective HIV vaccine, 
given prior to sexual debut, is predicted to significantly curb adolescent infection rates. While adolescents have indicated willingness to 
participate in HIV vaccine trials, there are concerns around safety, uptake, adherence, and ethical and logistic issues.
Objectives. To initiate a national, multisite project with the aim of identifying obstacles to conducting adolescent HIV vaccine trials in 
South Africa (SA).
Method. A simulated HIV vaccine trial was conducted in adolescents aged 12 - 17 years across five SA research sites, using the already 
licensed Merck human papillomavirus vaccine Gardasil as a proxy for an HIV vaccine. Adolescents were recruited at community venues 
and, following a vaccine discussion group, invited to participate in the trial. Consent for trial enrolment was obtained from a parent or legal 
guardian, and participants aged 16 - 17 years were eligible only if sexually active. Typical vaccine trial procedures were applied during the 
five study visits, including the administration of vaccination injections at study visits 2, 3 and 4.
Results. The median age of participants was 14 years (interquartile range 13 - 15), with 81% between the ages of 12 and 15 years at enrolment. 
Overall, 98% of screened participants opted to receive the vaccine, 588 participants enrolled, and 524 (89%) attended the final visit.
Conclusions. This trial showed that adolescents can be recruited, enrolled and retained in clinical prevention trials with parental support. 
While promising, these results were tempered by the coupling of sexual-risk eligibility criteria and the requirement for parental/guardian 
consent, which was probably a barrier to the enrolment of high-risk older adolescents. Further debate around appropriate consent 
approaches for such adolescents in HIV prevention studies is required.
S Afr Med J 2018;108(4):291-298. DOI:10.7196/SAMJ.2018.v108i4.12909
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potential means of curbing the epidemic.[7] Simultaneous licensure 
of an efficacious prophylactic HIV vaccine for both adults and 
adolescents is important; however, testing of a candidate vaccine 
in adolescent populations is likely to be required for age-specific 
licensure.[8,9] Compared with adults, adolescents may exhibit different 
vaccination-induced immune responses and safety profiles, and show 
differences in vaccine uptake and effectiveness.[8] While vaccine 
safety and efficacy is a biomedical concern, broader issues relating 
to adolescent participation in clinical trials must be considered, 
including uptake, ethical, sociobehavioural and logistic challenges. [9-15]
To date, no clinical HIV vaccine trials have involved adolescents, 
although a number of preparatory and acceptability studies have 
been reported. This work has focused on the acceptability of a 
preventive HIV vaccine[16-18] and of adolescent participation in 
vaccine trials. [16,19-24] Proposed models of adolescent inclusion in HIV 
vaccine trials suggest that the eligibility age for study participants 
may be rolled down to 16 - 18 years once safety and immunogenicity 
are established in adult efficacy trials, along with phase 1 - 2 
bridging safety and immunogenicity trials for younger age groups. 
Research conducted in SA indicates that hypothetical willingness for 
adolescent participation in vaccine trials is high for various reasons, 
but concerns remain.[19,20,22,23,25] Several studies have also focused on 
issues relating to feasibility of research in adolescents, including the 
viability of recruiting high-risk adolescents for efficacy trials. Most 
have used observational cohorts where the intervention is HIV 
testing and incidence and retention are the main outcomes.[26-29] 
While these studies provide useful preliminary data, it is important 
to note their limitations. Attitudes alone are unlikely to predict 
behaviour, and the value of examining ‘willingness to participate’ in 
a vaccine trial and its predictors is therefore limited.[29] Additionally, 
recruiting an observational cohort may not adequately reflect 
challenges arising from providing an experimental product to 
adolescents in a clinical setting.
Objectives
In order to develop an authentic understanding of the issues 
related to running HIV vaccine trials in adolescents, we initiated a 
national, multisite project with the broad objective of identifying 
clinical, community, ethical, legal and sociobehavioural obstacles 
to the conduct of adolescent HIV vaccine trials in SA and building 
capacity to address these, through the enactment of a simulated 
HIV vaccine trial. This study used the Merck human papillomavirus 
(HPV) vaccine Gardasil, already licensed but not yet available at the 
time, as a proxy for an HIV vaccine in adolescents in SA. The use 
of a registered vaccine with established safety and immunogenicity 
enabled focus on key feasibility questions such as recruitment, 
consent, retention, uptake and completion of a vaccine schedule; 
risk behaviours and HIV, sexually transmitted infection (STI) and 
pregnancy incidence in the cohort; and exploration of models for 
adolescent inclusion in HIV vaccine trials.
Methods
The study was a multisite, open-label longitudinal cohort of 12 - 
17-year-old, HIV-negative male and female adolescents. Sites at five 
SA HIV research organisations participated in this study: Desmond 
Tutu HIV Foundation, Cape Town; CAPRISA (Centre for the AIDS 
Programme of Research in South Africa), Durban; Perinatal HIV 
Research Unit, Soweto; MeCRU Clinical Research Unit, Pretoria; and 
The Aurum Institute, Rustenberg. These research sites are located 
in low-income, rural and urban areas with high HIV incidence 
rates. Adolescents were recruited through community outreach 
by targeting schools, youth groups, taxi ranks and other points of 
community convergence. Adolescents were also reached through 
their parents via outreach recruitment leaflets and activities.
Throughout, procedures simulating those of a typical HIV 
vaccine trial were adhered to as far as possible. Adolescents and 
parents were invited to attend vaccine discussion groups (VDGs) 
where information was provided on study procedures (including 
randomisation and blinding concepts to replicate an actual vaccine 
trial), HPV and the HPV vaccine. Following the VDG, attendees 
were invited to attend a screening visit. The age of consent to health 
research in SA is 18 years, and as the age eligibility criterion was 17 
at screening, all potential participants were therefore required to 
sign assent forms after their parent/guardian signed a consent form 
for their child’s enrolment. Both completed a questionnaire that 
assessed understanding of the study objectives and procedures, where 
continuation of study participation was dependent on achievement 
above a minimum score threshold. This assessment of understanding 
was re-administered to participants at the end of the study (month 9).
All participants were required to be HIV-negative at screening, and 
females could not be pregnant or breastfeeding. In order to simulate 
the potential requirements of an HIV vaccine trial, participants aged 
≥16 years (the age at which adolescents can lawfully consent to sex in 
SA) were required to be sexually active (defined as ever having had 
vaginal or anal sex). Sexual debut was not required as an eligibility 
criterion in youth aged 12 - 15 years. Sexually active females were 
encouraged to use hormonal and/or barrier contraception throughout 
the vaccine schedule, and both contraceptive methods were provided 
to participants. To safeguard adolescent privacy, parents/guardians 
were clearly told which clinical information they would and would 
not be party to as the trial continued.[30,31] Adolescents meeting 
the study criteria were enrolled and opted (with parental/guardian 
consent) to receive the HPV vaccine or not. Both those receiving and 
those not receiving the vaccine underwent identical study procedures 
apart from vaccine administration, such as perceived risks and 
benefits, age, gender, and knowledge of disease and vaccine, in order 
to determine correlates between vaccine uptake and refusal.
Participants attended five visits in total: screening, enrolment 
within 45 days of screening (first administration of vaccine), 
3 months (second administration of vaccine), 6 months (final 
administration of vaccine), and 9 months (final follow-up including 
an assessment of study understanding). At each visit, HIV 
counselling and testing, syphilis screening and pregnancy testing 
for females were conducted and sexual risk behaviour was assessed. 
STI symptoms were recorded at every visit. HIV testing utilised 
rapid finger-prick antibody-based tests and followed national 
HIV testing guidelines,[32] while an RPR (rapid plasma reagin) 
test was used to screen for syphilis. The HPV vaccine schedule 
was paused for females who became pregnant after enrolment, 
but was continued for participants who seroconverted during the 
study. Sexual risk behaviour was assessed through a quantitative 
questionnaire designed specifically for this study and administered 
by research staff in the participant’s home language.
Ethical considerations
Ethical approval was obtained from the human research ethics 
committees of the University of Cape Town (ref. no. 245/2008), the 
University of the Witwatersrand (ref. no. 080710), the Uni versity of 
KwaZulu-Natal (ref. no. BF109/08) and the University of Limpopo 
(ref. no. MREC/P/110/2009). When study procedures identified HIV 
infection, steps were taken to counsel participants, ensure timely 
participant disclosure to a trusted adult, and link participants to care. 
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Efforts were made to reduce the risk of HIV infection of enrolled 
participants, and assistance was provided to participants with syphilis 
or those who became pregnant while enrolled. There was engagement 
with participating community representatives, including community 
advisory board youth representatives, as recommended for adolescent 
prevention trials.[31-37]
Statistical analysis
Data were analysed using Stata 14.0 (StataCorp, USA). Participants 
were divided into two age groups, using age at enrolment (12 - 
15 and 16 - 17 years), based on the different inclusion criteria 
regarding sexual activity. The assessment of understanding score was 
calculated as the number of correct answers to 13 questions. Bivariate 
analysis employed Student’s t-test, Fisher’s exact test and the χ2 test 
of proportions, as appropriate; for intra-individual comparisons 
of measures taken at baseline and 9 months, McNemar’s χ2 test, 
McNemar’s exact test and paired t-tests were used. The incidences of 
pregnancy and HIV seroconversion were calculated as the number of 
incidence events divided by total person-time of follow-up. Survival 
analyses, including Kaplan-Meier tables and Cox’s proportional 
hazards models, were used to determine factors associated with 
loss to follow-up in the cohort. All statistical tests were two-sided 
at α=0.05. Owing to delayed starts and study funding contracts, the 
study procedures were halted for a number of participants (mainly 
from two sites) prior to their scheduled follow-up completion. These 
individuals completed their vaccine schedules, but no further study 
data were collected. Analyses of retention (defined as completion of 
all five study visits), vaccine completion and follow-up behaviours 
excluded these participants.
Results
Cohort description
Screening and enrolment took place from November 2009 to October 
2010, with staggered site initiation and mean recruitment of 168 
participants per site over 8.4 months (Fig. 1). Of the 961 adolescents 
screened across the five sites, 844 (87.8%) were enrolled (Table 1). 
The majority of adolescents who enrolled were in the 12 - 15-year-
old age group (81%). The median age of enrolled participants 
was 14  years (interquartile range (IQR) 13 - 15) at screening, and 
61% were female. The mean assessment of understanding score at 
enrolment was 11.3 out of 13 (IQR 11 - 12). The most common 
reasons for failure of screening across all sites were adolescents 
Screening
Enrolment
2-month visit
6-month visit
9-month visit
Enrolment ≥9 months 
prior to site closure
961
844
812
(96.2%)
705
(83.5%)
530
(62.8%)
588
582
(99.0%)
565
(96.1%)
824
(89.1%)
Total
Fig. 1. Participant visit attendance and retention by site.
Table 1. Baseline demographics and sexual risk behaviour by age group
Variable
Age (years), n (%)
Total (N=843) p-value
12 - 15 (N=684, 
81%)
16 - 17 (N=159, 
19%)
Gender female, n (%) 420 (61) 90 (57) 510 (61) 0.27
Ever had sex, n (%) 58/674 (9) 135/157 (86) 193/ 831 (23) <0.001
Age (years) at first sex, median (IQR) 14 (12 - 15) 
(n=56)
15 (15 - 16)
(n=135)
15 (14 - 16)
(N=191)
<0.001
Number of sexual partners, median (IQR) 1 (1 - 1)
(n=53)
1 (1 - 2)
 (n=132)
1 (1 - 2)
(N=185)
0.16
Of all the times had sex, frequency of condom use, n (%) 0.002
Always 30/57 (53) 94/135 (70) 124/192 (64)
Usually 5/57 (9) 5/135 (4) 10/192 (5)
About half the time 3/57 (5) 16/135 (12) 19/192 (10)
Rarely 1/57 (2) 6/135 (4) 7/192 (4)
Never 18/57 (32) 14/135 (10) 32/192 (17)
Ever engaged in transactional sex, n (%)
Received 2/55 (4) 2/135 (1.5) 4/190 (2) 0.58
Given 1/57 (2) 3/133 (2) 4/190 (2) 1.00
Ever had sex with someone without knowing their HIV status, n (%) 32/56 (57) 79/134 (59) 111/190 (58) 0.82
Has someone ever used force to make you have sex, n (%) 6/57 (11) 11/134 (8) 17/191 (9) 0.61
Ever had an STI, n (%) 2/56 (4) 3/129 (2) 5/185 (3) 0.64
Ever had sex while drunk or under the influence of a drug, n (%) 3/57 (5) 16/132 (12) 19 /189 (10) 0.19
IQR = interquartile range; STI = sexually transmitted infection.
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aged 16 - 17 years not being sexually active (n=46 participants) or 
participants being lost to follow-up after arriving without a biological 
parent or legal guardian and then never returning or not being 
contactable afterwards (n=273).
Owing to delayed starts at the sites and study funding contracts, 
256 participants (30%) were not enrolled in time to finish the full five 
visits. When those who completed the full 9 months of study time 
were compared with those who enrolled late, these participants did 
not differ in terms of age, gender or reporting at baseline ever having 
had sex. Baseline data from all 843 participants are presented in Table 
1. Participants who could not complete 9 months of follow-up owing 
to termination of study procedures (n=256) were excluded from 
assessments of retention and vaccine completion (Fig. 2). This early 
closure mainly affected two sites.
Sexual risk behaviour and assessment of understanding
Table 1 shows baseline sexual risk behaviour of participants as 
reported in self-administered questionnaires by the two eligibility age 
groups, 12 - 15 and 16 - 17 years. Of the participants, 23% reported 
ever having had sex, of whom 9% were 12 - 15 years old. Despite the 
eligibility requirement, only 86% of 16 - 17-year-olds reported sexual 
activity at baseline. The median age of sexual debut was lower in the 
younger age group (14 v. 15 years; p<0.0001). Consistent condom use 
increased with age, with 12 - 15-year-old sexually active participants 
significantly less likely to have used condoms than 16 - 17-year-
olds (10% v. 32%, respectively; p=0.002). There were no statistically 
significant differences across other baseline sexual risk indicators 
between the age groups.
Table 2 reports changes in sexual risk behaviour from baseline 
to study end. This analysis was restricted to those participants who 
attended the study visit at month 9, and mainly focused on questions 
regarding sexual activity ‘in the past 6 months’. Within the age groups, 
the only statistically significant change was a reported increase in the 
number of 12 - 15-year-olds ever having had sex (p=0.01). However, 
as the numbers of match pairs reporting sexual activity were small, 
we also assessed changes across all participants at baseline and those 
retained at 9 months. Borderline improvement was noted in the 
proportions of participants who reported using condoms ‘always’ or 
‘usually’ from baseline to study end (74% to 86%; p=0.05), while the 
number who reported ‘never’ using a condom fell significantly (12% 
to 1.4%; p=0.001). Compared with baseline, at the end of the study 
more participants reported having had sex with someone known 
to be HIV-positive (0% to 4%; p=0.03). Mean assessment of study 
procedure understanding scores decreased from 11.3 at baseline to 
11.1 at 9 months (paired t-test: p=0.001), and this decrease was noted 
across both age groups.
Cohort retention
Fig. 3 depicts a Kaplan-Meier curve of participant retention over the 
study period, stratified by the two age groups. Considering only the 
participants who had the potential to complete all five sessions before 
study termination, overall retention (defined as attendance at all five 
study visits) was 89%. There was no difference in retention between 
the two groups (88% in the younger group v. 87%; log-rank test: 
p=0.55). Retention was not associated with gender or with reporting 
being sexually active at baseline (Table 3); however, attrition had a 
borderline association with baseline reports of having ever had sex 
while drunk or under the influence of drugs (p=0.06) (Table 3). There 
was no association between baseline assessment of understanding 
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Fig. 2. Cumulative number enrolled by site: Desmond Tutu HIV Foundation 
(DT), Cape Town; MeCRU Clinical Research Site, Pretoria; Centre for 
the AIDS Programme of Research in South Africa (CAPRISA), Durban; 
Perinatal HIV Research Unit (PHRU), Soweto, Johannesburg; and The 
Aurum Institute, Rustenburg. 
Table 2. Change in sexual risk behaviour over time (enrolment to study end in participants retained for 9 months)
Variable
Age (years)
12 - 15 (N=422) 16 - 17 (N=100)
N Baseline 9 months p-value N Baseline 9 months p-value
Ever had sex, n (%) 422 33 (8) 48 (11) 0.001 100 87 (87) 87 (87) 1.00
Had sex in past 6 months, n (%) 24 9 (38) 10 (42) 1.00 74 47 (64) 43 (58) 0.54
Frequency of condom use in the past 6 months, n (%) 8 37 0.50
Always 4 (50) 5 (63) 28 (76) 27 (73)
Usually 2 (25) 2 (25) 0 (0) 4 (11)
About half the time 2 (25) 0 (0) 6 (16) 5 (14)
Rarely 0 (0) 1 (13) 1 (3) 1 (3)
Never 0 (0) 0 (0) 1.00 2 (5) 0 (0)
In the past 6 months have you had, n (%)
Transactional sex
Received 7 0 (0) 0 (0) 1.00 35 2 (61) 3 (9) 1.00
Given 8 0 (0) 0 (0) 1.00 34 1 (3) 2 (6) 1.00
Sex with someone known to be HIV positive 8 0 (0) 0 (0) 1.00 35 0 (0) 1 (3) 1.00
Sex with someone without knowing their HIV status 8 4 (50) 4 (50) 1.00 36 19 (53) 13 (36) 0.29
Sex while drunk or under the influence of a drug 7 1 (14) 0 (0) 1.00 35 3 (9) 5 (14) 0.73
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scores and attrition (p=0.94). Reasons why some participants were 
lost to follow-up were not recorded.
HIV, STI and pregnancy incidence
Ten pregnancies occurred over the study period, with a total of 
511.6 years of follow-up time accumulated across all five sites, giving 
an incidence rate of 1.95 per 100 person-years (95% confidence 
interval (CI) 0.9 - 3.6). Five of the 10 pregnant participants reported 
contraceptive use at enrolment, 3 using male condoms, 3 using 
the female condom, and 3 using injectable contraceptives (one 
participant used two of these methods, and one three). Females who 
had their sexual debut prior to study participation were more likely 
to become pregnant (odds ratio 5.09, 95% CI 1.4 - 18.21). Six of the 
10 participants who became pregnant prior to the 6- or 9-month 
appointment were lost to follow-up.
The trial was conducted in areas with a high HIV burden, 
and HIV seroconversion occurred in two participants, although 
one participant seroconverted between screening and enrolment, 
suggesting that she was in the window period at screening. Based 
on the one incident infection, which was detected at month 9, the 
incidence was 0.20 per 100 person-years (95% CI 0.005 - 1.1). Both 
seroconverters were female, aged 13 and 15 years. Syphilis testing was 
conducted at each study visit and overall only one participant tested 
positive for syphilis, at the time of enrolment.
Vaccinations
Overall, 826 (98%) of participants with parental/guardian consent 
agreed to receive the HPV vaccine. Of the 580 participants who were 
consented and enrolled at least 9 months prior to study termination, 
532 (92%) completed the full HPV vaccination schedule.
Discussion
This study proved the feasibility of recruiting and retaining 
adolescents in a clinical trial in which a multidose ‘STI’ vaccine was 
administered to participants, emulating an adolescent HIV vaccine 
trial. This study supports a model of adolescent inclusion in HIV 
vaccine trials where, once a potential vaccine regimen is considered 
safe and immunogenic in adult efficacy studies, the eligibility age 
for study participation may be ‘rolled down’ to 16 - 18 years in order 
to be inclusive of younger participants (shown in Fig. 4).[21,33] Phase 
1 - 2 bridging studies for safety and immunogenicity can then be 
designed for younger adolescent age groups in whom sexual activity 
has not yet commenced. Minor adolescent participants could then 
contribute to safety and immunogenicity data without contributing 
to efficacy data.
To date, HIV prevention trials have targeted adults at high risk 
for HIV acquisition by enrolling individuals who have multiple sex 
partners, partners of unknown or positive HIV serostatus, or sex 
without condoms. In this study, we asked only that older adolescents 
(aged 16  - 17 years) be sexually active, as 16 is the age of consent 
to sex in SA and inclusion of such a criterion would have had legal 
implications. Sexual activity is no longer a reportable offence when 
younger adolescents engage in sex with peers, or with an older 
partner where the age difference is less than 2 years; however, parental 
and societal pressure remains a barrier to high-risk adolescents 
acknowledging sexual activity and taking part in such trials when 
parental consent is required.[35,38] Although 961 adolescents were 
recruited in this study, sexual eligibility criteria combined with the 
need for parental consent may have influenced the age distribution, 
as the majority had not initiated sexual activity and only 19% of the 
enrolled sample fell within the 16 - 17-year age group. There is a need 
for study investigators, institutional ethics bodies and regulators to 
consider alternative approaches for the inclusion of older adolescents 
that do not involve parental consent.
The trial was modelled on previous adolescent HPV vaccine 
licensure studies, and in order to mimic the likely consent approach 
for an HIV vaccine trial, participants in our study required parental/
guardian consent to enrol. In the VDGs, the HPV vaccine was 
portrayed as a vaccine to prevent a sexually transmitted infection 
in order to fit with a simulated HIV vaccine design. At the time of 
protocol design, consultations and discussions were held around the 
dynamic ethicolegal framework of SA research, laws and involvement 
of minors, and these discussions have led to a number of important 
publications.[31,34-37] This study suggests that the requirement for 
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Fig. 3. Kaplan-Meier graph of retention, stratified by age group. (*Age at screening.)
Table 3. Bivariate association of baseline demographics and sexual risk behaviours with attrition
Variable
Bivariate analysis
HR (95% CI) p-value
Age at enrolment 1.09 (0.93 - 1.29) 0.25
Gender female 0.59 (0.25 - 1.39) 0.66
Ever had sex 1.36 (0.67 - 2.384) 0.29
Ever engaged in transactional sex
Received  - 1.00
Given  - 1.00
Ever had sex with someone without knowing their HIV status 0.92 (0.34 - 2.41) 0.86
Has someone ever used force to make you have sex 3.05 (0.70 - 13.33) 0.14
Ever had sex while drunk or under the influence of a drug 2.97 (0.97 - 9.12) 0.06
HR = hazard ratio; CI = confidence interval.
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parental/guardian consent coupled with 
the requirement for older adolescents to be 
sexually active may have been an obstacle 
to recruitment of high-risk adolescents, 
owing to awareness of sexual activity on the 
part of the parents/guardians and resultant 
discomfort between the adults and the 
adolescents. Had a proportion of participants 
in the 16 - 17-year-old age group been pre-
stipulated, recruitment may have been more 
challenging. Going forward, this ‘dilution 
of incidence’ effect should be catered for 
by limiting the number of adolescents in 
the adult trial (Fig. 4) and/or factoring in a 
lower incidence contribution from this age 
group. Alternatively, ways should be explored 
to identify high-risk young individuals 
without requiring disclosure of behaviours 
to guardians.
HIV incidence
Overall, self-reported sexual risk behaviour at 
study onset was low, and HIV incidence was 
particularly low relative to SA standards at 
0.20 per 100 person-years. This is lower than 
the estimated incidence of 0.56/100 person-
years in 15 - 18-year-olds mathematically 
derived from prevalence data by Shishana et 
al.,[39] as well as lower than that observed in 
a 16 - 20-year-old cohort study in a similar 
setting (9.2/100 person-years).[22] It also 
contrasts with vaccine preparedness studies, 
where behavioural data suggest that individuals 
volunteering for vaccine-related research may 
be more likely to be at risk of HIV than those 
who do not volunteer. Smit et al.[24] compared 
risk profiles of individuals volunteering for an 
HIV vaccine preparedness cohort with those 
of a community sample. Adjusting for age, 
gender, education and risk perception, cohort 
participants were younger, more likely to have 
been treated for an STI, and less likely to use 
condoms. Jaspan et al.[20] also found high risk 
levels in an 11 - 19-year-old adolescent cohort, 
with one-third having experienced sexual 
debut (at a mean age of 14.6 years) and an HIV 
prevalence rate of 10.6%.[20] In a 12-month 
follow-up of 14 - 17-year-olds, Jaspan et al.[40] 
found reports of high-risk behaviours and, 
although no HIV seroconversions occurred, 
the occurrence of five pregnancies supported 
reports of unprotected sex.[40] Parental/
guardian consent was waived in this latter study. 
Furthermore, participation of adolescents in 
this study who were sexually active with full 
parental knowledge may imply that they were 
more self-efficacious individuals, and so more 
likely to engage in safer sex practices.
Sexual risk behaviour
The study findings highlight the challenges 
of collecting accurate, authentic sexual risk 
behaviour data from adolescents. The dis-
crepancy between the eligibility requirement 
for sexual activity in 16 - 17-year-olds and the 
reporting of this behaviour in only 87% of the 
cohort may reflect either misunderstanding 
by some adolescents or inaccuracies around 
behaviour reporting at the time of enrol-
ment or questionnaire completion. Recent 
prevention trials in adult women in SA have 
highlighted that a strong reason for individual 
participation is the access to improved health 
services that clinical research offers. In this 
case, access to an otherwise unavailable vac-
cine may have prompted young people to 
report behaviours inaccurately.
At baseline, reported condom use 
improved with increasing age. This find-
ing suggests that adolescents become more 
skilled at negotiating condom use as they 
become more sexually experienced, while 
younger adolescents may be less prepared 
for or anticipating of sex. However, sexual 
activity in the youngest age group was infre-
quent and results from this group should be 
interpreted with caution. By the end of the 
study, improvements in condom use were 
observed, which may be due to increasing 
age, preparedness for and experi ence with 
sex (as before) or to study participation, as 
risk reduction counselling, HIV testing and 
condoms were provided at every visit.
In addition, by the end of the study more 
participants reported knowing their partners’ 
serostatus. This may be a function of more 
prevalent testing as adoles cents get older and 
begin to engage with older partners, or also a 
result of study participation. Risk behaviours 
are studied repeatedly throughout preven-
tion trials because the concern remains that 
participation may cause sexual disinhibition, 
where individuals exhibit increased risk 
behaviour owing to perceived protection. 
This concern is repeatedly raised in the 
context of youth involvement in clinical 
prevention trials. However, clinical trials in 
adults have consistently shown reduced risky 
behaviour during trial participation, and 
although adolescents are more challenging 
to study, owing to natural developmental 
and behaviour changes, our data showed no 
evidence of behavioural disinhibition.
In contrast to HIV rates, the pregnancy 
incidence in this cohort was relatively high. 
This suggests the practice of condomless 
sex coupled with age-related lower HIV 
risk networks. It is possible that young 
women are on the brink of exposure to 
sexual partners who will place them at risk 
of HIV infection as well as pregnancy, again 
emphasising the urgent need for a protective 
vaccine before this occurs.
Trial retention
Retention in the study was 89%. Previous 
studies reported retention rates of 87% in 
a 16 - 20-year-old cohort[22] and 82% in 
a 14 - 17-year-old cohort,[40] each followed 
for 12 months. Adolescence is a challenging 
age for trial retention owing to competing 
priorities, busy schedules and structural 
impediments, as well as evolving autonomy 
and independence. Capacity building was 
initially undertaken to ensure that all trial 
sites were competent to enrol adolescents 
and that all would be safe, friendly and 
attractive to adolescents.[41] Perception of the 
value of the HPV vaccine, both costly and at 
the time inaccessible to most SA adolescents, 
may have contributed to the high retention 
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Fig. 4. A modelled approach to introducing adolescent clinical vaccine trials over time, adapted from 
that proposed by Lau et al.[33]
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rate. Albeit unavailable, the vaccine used was known to be safe and 
effective, and this may have contributed to the high retention rate. It 
is not known how willingness of this age group to participate would 
have been affected if an experimental vaccine product of unknown 
efficacy had been offered.
Although the marginal decrease in assessment of understanding 
scores across the study period was statistically significant, we doubt 
that it is clinically significant. Regardless, this is a reminder that 
informed consent is an ongoing process that should be informally 
evaluated at every study visit. While vaccine discussion groups can 
bolster understanding, the way in which information is initially 
imparted and ongoing reminders of details over time are particularly 
important for long clinical trials. This may be especially true for 
adolescents, who can have difficulty in grasping information, and 
concepts should be revisited to ensure ongoing informed consent.
It is worth noting here that SA now conducts a national HPV 
vaccination programme in adolescents, and HPV vaccine uptake 
and completion rates have been excellent and above those reported 
from other countries.[42,43] Qualitative focus group research in SA had 
highlighted the concerns of mothers regarding agreement to HPV 
vaccination of their daughters,[44] yet this did not appear to affect 
behaviour in the present study, with 98% of participants and their 
parents opting to receive the HPV vaccine. This is remarkable, because 
the HPV vaccine was framed in this study as a means to prevent STI, 
rather than the more palatable cancer prevention message.
This study augurs well for an extended vaccine schedule in 
adolescents, providing useful information both for HPV vaccine roll-
out in SA and for planning future adolescent HIV vaccine trials.[45,46] 
This is particularly relevant in the context of the phase IIb/III HVTN 
702 vaccine trial in SA, which will evaluate the efficacy and safety of 
a clade C ALVAC HIV and bivalent subtype C gp120/MF59 vaccine. 
Success in the phase IIb/III trial will pave the way for extension of the 
trial to adolescent participants. If the adolescent trial is successful, 
there could be potential for an effective, school-based, dual HPV/
HIV vaccine programme in SA.
Conclusions
The use of an HPV vaccine as a surrogate for an HIV vaccine has 
shown that adolescents aged 12 - 17 years can be successfully and 
easily recruited, enrolled and retained in clinical prevention trials 
in both rural and peri-urban SA, including trials framed as STI 
prevention (Fig. 3). In this study, the parental/guardianship consent 
strategy, combined with sexual-risk eligibility criteria, may have acted 
as a barrier to the enrolment of older high-risk adolescents. This 
suggests that HIV prevention studies enrolling high-risk, sexually 
active adolescents must carefully consider the most appropriate 
consent approach. National ethical guidelines allow a waiver of 
parental/guardianship consent for adolescent studies where specific 
criteria are met, including that study procedures pose minimal 
risk. SA is currently enrolling adults only into the first HIV vaccine 
licensure study.[47] It is clear that should this vaccine be even partially 
efficacious, the question of licensure in adolescents will be key. One 
option for HIV vaccine trials is that minor adolescent participants 
could contribute safety and immunogenicity data only without 
contributing to efficacy data, but there may be alternative approaches 
to include older at-risk adolescents that will require the consent 
strategy to be discussed with institutional ethics bodies and the 
regulators who ultimately license the product.
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